China Pharma Holdings PE Ratio 2012-2026 | CPHI
Current and historical p/e ratio for China Pharma Holdings (CPHI) from 2012 to 2026. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. China Pharma Holdings PE ratio as of June 19, 2026 is 0.00.
| China Pharma Holdings PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-06-18 | 0.77 | 0.00 | |
| 2026-03-31 | 0.61 | $-0.54 | 0.00 |
| 2025-12-31 | 1.21 | $-0.74 | 0.00 |
| 2025-09-30 | 1.95 | $-1.01 | 0.00 |
| 2025-06-30 | 1.79 | $-1.49 | 0.00 |
| 2025-03-31 | 2.63 | $-2.22 | 0.00 |
| 2024-12-31 | 2.33 | $-2.70 | 0.00 |
| 2024-09-30 | 2.36 | $-2.06 | 0.00 |
| 2024-06-30 | 2.49 | $-4.31 | 0.00 |
| 2024-03-31 | 3.71 | $-6.92 | 0.00 |
| 2023-12-31 | 1.21 | $-9.10 | 0.00 |
| 2023-09-30 | 1.48 | $-19.10 | 0.00 |
| 2023-06-30 | 3.41 | $-24.20 | 0.00 |
| 2023-03-31 | 3.90 | $-29.70 | 0.00 |
| 2022-12-31 | 9.59 | $-37.80 | 0.00 |
| 2022-09-30 | 13.00 | $-35.00 | 0.00 |
| 2022-06-30 | 21.46 | $-37.00 | 0.00 |
| 2022-03-31 | 39.00 | $-38.00 | 0.00 |
| 2021-12-31 | 48.26 | $-37.00 | 0.00 |
| 2021-09-30 | 55.85 | $-45.00 | 0.00 |
| 2021-06-30 | 72.32 | $-45.00 | 0.00 |
| 2021-03-31 | 84.00 | $-35.00 | 0.00 |
| 2020-12-31 | 44.58 | $-35.00 | 0.00 |
| 2020-09-30 | 36.48 | $-235.00 | 0.00 |
| 2020-06-30 | 66.63 | $-235.00 | 0.00 |
| 2020-03-31 | 50.39 | $-245.00 | 0.00 |
| 2019-12-31 | 23.68 | $-240.00 | 0.00 |
| 2019-09-30 | 24.51 | $-115.00 | 0.00 |
| 2019-06-30 | 32.34 | $-125.00 | 0.00 |
| 2019-03-31 | 33.18 | $-125.00 | 0.00 |
| 2018-12-31 | 25.74 | $-125.00 | 0.00 |
| 2018-09-30 | 20.42 | $-195.00 | 0.00 |
| 2018-06-30 | 21.99 | $-200.00 | 0.00 |
| 2018-03-31 | 31.71 | $-215.00 | 0.00 |
| 2017-12-31 | 17.56 | $-220.00 | 0.00 |
| 2017-09-30 | 17.50 | $-95.00 | 0.00 |
| 2017-06-30 | 23.00 | $-90.00 | 0.00 |
| 2017-03-31 | 26.00 | $-95.00 | 0.00 |
| 2016-12-31 | 26.00 | $-105.00 | 0.00 |
| 2016-09-30 | 21.50 | $-250.00 | 0.00 |
| 2016-06-30 | 24.00 | $-195.00 | 0.00 |
| 2016-03-31 | 17.00 | $-150.00 | 0.00 |
| 2015-12-31 | 15.69 | $-175.00 | 0.00 |
| 2015-09-30 | 19.84 | $-250.00 | 0.00 |
| 2015-06-30 | 35.99 | $-360.00 | 0.00 |
| 2015-03-31 | 34.00 | $-475.00 | 0.00 |
| 2014-12-31 | 30.01 | $-455.00 | 0.00 |
| 2014-09-30 | 25.09 | $-325.00 | 0.00 |
| 2014-06-30 | 38.50 | $-275.00 | 0.00 |
| 2014-03-31 | 50.50 | $-225.00 | 0.00 |
| 2013-12-31 | 34.50 | $-230.00 | 0.00 |
| 2013-09-30 | 28.00 | $-115.00 | 0.00 |
| 2013-06-30 | 21.00 | $-75.00 | 0.00 |
| 2013-03-31 | 29.00 | $-5.00 | 0.00 |
| 2012-12-31 | 20.20 | $55.00 | 0.37 |
| 2012-09-30 | 36.50 | $110.00 | 0.33 |
| 2012-06-30 | 34.00 | $150.00 | 0.23 |
| 2012-03-31 | 68.00 | $190.00 | 0.36 |
| 2011-12-31 | 67.00 | $220.00 | 0.30 |
| 2011-09-30 | 97.00 | $250.00 | 0.39 |
| 2011-06-30 | 225.00 | $265.00 | 0.85 |
| 2011-03-31 | 253.00 | $275.00 | 0.92 |
| 2010-12-31 | 303.00 | $270.00 | 1.12 |
| 2010-09-30 | 249.00 | $230.00 | 1.08 |
| 2010-06-30 | 275.00 | $245.00 | 1.12 |
| 2010-03-31 | 333.00 | $225.00 | 1.48 |
| 2009-12-31 | 385.00 | $215.00 | 1.79 |
| 2009-09-30 | 340.00 | $245.00 | 1.39 |
| 2009-06-30 | 145.00 | $210.00 | 0.69 |
| 2009-03-31 | 131.00 | $210.00 | 0.62 |
| 2008-12-31 | 114.00 | $220.00 | 0.52 |
| 2008-09-30 | 208.00 | $205.00 | 1.01 |
| 2008-06-30 | 202.00 | $195.00 | 1.04 |
| 2008-03-31 | 230.00 | $190.00 | 1.21 |
| 2007-12-31 | 305.00 | $170.00 | 1.79 |
| 2007-09-30 | 180.00 | $170.00 | 1.06 |
| 2007-06-30 | 170.00 | $155.00 | 1.10 |
| 2007-03-31 | 188.00 | $135.00 | 1.39 |
| 2006-12-31 | 227.00 | $125.00 | 1.82 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.026B | $0.004B |
| CHINA PHARMA HOLDINGS, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular and CNS diseases, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd. (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |